Logo 1 Logo 2

Investigational Drug Details

Drug ID: D155
Drug Name: Zanamivir
Synonyms:
Type: small molecule
DrugBank ID: DB00558
DrugBank Description: A guanido-neuraminic acid that is used to inhibit neuraminidase.
PubChem ID: 60855
CasNo: 139110-80-8
Repositioning for NAFLD: Yes
SMILES: [H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO
Structure:
InChiKey: ARAIBEBZBOPLMB-UFGQHTETSA-N
Molecular Weight: 332.3098
DrugBank Targets: Neuraminidase; Neuraminidase; Sialidase-2
DrugBank MoA: The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
DrugBank Pharmacology: Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.
DrugBank Indication: For the prevention and treatment of influenza A and B.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: